Presentation is loading. Please wait.

Presentation is loading. Please wait.

Growth inhibition rate with patritumab

Published byDulcie McDowell Modified over 5 years ago

Similar presentations

Presentation on theme: "Growth inhibition rate with patritumab"— Presentation transcript:

1 Growth inhibition rate with patritumab
SupplementTable.1 Cell line Growth inhibition rate with patritumab Histology Genomic mutation QG56 40.8 Sq HARA 38.7 SW900 33.0 H1944 32.3 Ad H358 31.7 KRAS A549 27.2 PC10 21.3 H2172 13.6 H1355 10.2 H1975 8.0 EGFR HCC78 6.9 ROS1 fusion PC1 6.0 PC9ZD < 5 H1703 Ad-sq Ma70 H1650 H1581 H441 H2009 Sk-Lu-1 Ma70GR H1435 H460 Calu6 H1573 RERF-LCA1 H1993 MET amp 11-18 H1838 HCC827 HCC827GR5 EGFR, MET amp H228 H23 H226 LK2 PC14 H2122 Calu1 Sq-1 H596 EBC1 MET ampl H520 HCC4006 H3122 ALK fusion PC9 H1437 H2170 PC3

2 Genomic status of EGFR and MET
SupplementTable.2 Cell line Genomic status of EGFR and MET PC9 Ex19 L746_E750del　 HCC827 Ex19 L746_E750del H1650 HCC4006 Ex19 L747_E749del Ma70 Ex21 L858R Ma70GR 11-18 H1975 Ex21 L858R + Ex20 T790M PC9ZD Ex19 L746_E750del + Ex20 T790M　 HCC827GR5 Ex19 L746_E750del + MET amplification　

3 SupplementTable.3 Patients # Sex Age Best responses with EGFR-TKI
EGFR genomic status at pre-treatment Gefitinib or Erlotinib Progression Free Survival (Days) 1 Female 72 Complete Response Ex19 Del　 Gefitinib 542 2 82 Ex21 L858R 231 3 61 2067 4 81 Exon18 G719A 361 5 70 Ex19 Del 304 6 Male 63 Progressive disease 58 7 69 Erlolitinib 28 8 9 10 65 Partial Response 639 11 62 155 12 202 13 55 172 14 79 244

4 SupplementTable.4 EGFR mutation Resistance mechanism IC50
IC50 (+patritumab) PC9HRG Ex19 deletion aberrant heregulin expression 3.4μM 0.54μM PC9ZD T790M mutation 3.1μM HCC827GR5 Ex21 point mutation met amplification >10μM

Download ppt "Growth inhibition rate with patritumab"

Similar presentations

James R. Rigas Comprehensive Thoracic Oncology Program

James R. Rigas Comprehensive Thoracic Oncology Program
Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.

Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.
Shyamala Maherswaran, Ph.D. et al. Sarah Gomez and Rachael Holmes Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.

Shyamala Maherswaran, Ph.D. et al. Sarah Gomez and Rachael Holmes Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.
Strategies to overcome resistance in NSCLC with driver mutations

Strategies to overcome resistance in NSCLC with driver mutations
In vivo animal model studies in biological science 1.Cancer 2. Neuroscience 1.Cancer research 2. Neuroscience.

In vivo animal model studies in biological science 1.Cancer 2. Neuroscience 1.Cancer research 2. Neuroscience.
The highlight of resistance mechanism of targeted therapy on clinical therapy Zuhua Chen Dep. of GI oncology.

The highlight of resistance mechanism of targeted therapy on clinical therapy Zuhua Chen Dep. of GI oncology.
Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract 11021. (Poster)

Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.

Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
Lung Cancer in Never-Smokers from the Princess Margaret Cancer Centre 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;

Lung Cancer in Never-Smokers from the Princess Margaret Cancer Centre 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;
Big Data in Genomics, Diagnostics, and Precision Medicine

Big Data in Genomics, Diagnostics, and Precision Medicine
Samsung Genome Institute Samsung Medical Center

Samsung Genome Institute Samsung Medical Center
Integrated genomic and proteomic analysis identifies PTEN loss and AKT/MTOR as drivers of resistance to MEK inhibitors in NSCLC cells Dianren Xia1, Lauren.

Integrated genomic and proteomic analysis identifies PTEN loss and AKT/MTOR as drivers of resistance to MEK inhibitors in NSCLC cells Dianren Xia1, Lauren.
Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.
Rosell R et al. Proc ASCO 2011;Abstract 7503.

Rosell R et al. Proc ASCO 2011;Abstract 7503.
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Drug concentration (μM)

Drug concentration (μM)
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Patient Case 1 Patient Case 1: PET/CT Scan.

Patient Case 1 Patient Case 1: PET/CT Scan.
Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

Similar presentations

Ads by Google